MARKET

MCRB

MCRB

Seres
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.60
+0.25
+3.94%
Opening 11:11 09/16 EDT
OPEN
6.26
PREV CLOSE
6.35
HIGH
6.70
LOW
6.24
VOLUME
920.32K
TURNOVER
--
52 WEEK HIGH
38.50
52 WEEK LOW
5.41
MARKET CAP
605.34M
P/E (TTM)
-4.4688
1D
5D
1M
3M
1Y
5Y
Why Seres Therapeutics Shares Are Trading Higher Today
Seres Therapeutics (NASDAQ:MCRB) shares are trading higher after the company achieved enrollment of 300 subjects in its Phase 3 ECOSPOR IV study of SER-109.
Benzinga · 19h ago
YY, NNVC and REKR among mid-day movers
Gainers: GreenSky (NASDAQ:GSKY) +53%. IronNet (NYSE:IRNT) +27%. Sphere (NASDAQ:ANY) +22%. Allied Healthcare Products (NASDAQ:AHPI) +19%. Actinium Pharmaceuticals (NYSE:ATNM) +16%. Ampio Pharmaceuticals (NYSE:AMPE) +15%. Inozyme Pharma (NASDAQ:INZY) +15%. S...
Seekingalpha · 21h ago
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. Difficile Infection
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, today announced it has achieved enrollment of 300 subjects with the ECOSPOR IV open-label study evaluating SER-109, an
Benzinga · 1d ago
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
Benzinga · 2d ago
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
CAMBRIDGE, Mass., September 07, 2021--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in three upcoming investor conferences:
Business Wire · 09/07 11:00
Cathie Wood's ARK Invest Posts Fund Sales For Monday, Aug. 30, 2021: IOVA, MCRB, ISRG, BABA, NXPI, GOOG, MELI, SE, PSTI, CLLS
Iovance Biotherapeutics (IOVA) - 71,749 Seres Therapeutics (MCRB) - 846,468 Intuitive Surgical (ISRG) - 1,700 Alibaba Group Golding (BABA) - 15,089 NXP Semiconductors (NXPI)
Benzinga · 08/31 14:57
Cathie Wood's ARK Invest Posts Fund Sales For Friday, Aug. 27, 2021: MCRB, NSTG, IOVA, BABA, LC, OKTA, CLLS, PSTI, BMY
Seres Therapeutics (MCRB) - 1,282,095  NanoString Technologies (NSTG) - 66,400  Iovance Biotherapeutics (IOVA) - 444,050  Alibaba Group (BABA) - 13,593  LendingClub (LC)
Benzinga · 08/30 14:39
Cathie Wood's ARK Invest Posts Fund Sales For Thursday, Aug. 26, 2021: NTDOY, IOVA, NSTG, SE, XONE, BABA, LC, SQ, OKTA, MCRB, PSTI, SEER, RHHBY, BMY, GOOG, TRMB
Nintendo (NTDOY) - 38,500 Shares Iovance Biotherapeutics (IOVA) - 302,190 NanoString Technologies (NSTG) - 144,340 Sea (SE) - 71,593 ExOne (XONE) - 10,000 Alibaba (BABA) - 46,900 LendingClub (LC) - 32,700 Square
Benzinga · 08/27 13:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MCRB. Analyze the recent business situations of Seres through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MCRB stock price target is 20.57 with a high estimate of 32.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 188
Institutional Holdings: 87.38M
% Owned: 95.27%
Shares Outstanding: 91.72M
TypeInstitutionsShares
Increased
57
3.67M
New
21
696.00K
Decreased
45
5.71M
Sold Out
27
2.22M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.52%
Pharmaceuticals & Medical Research
-0.69%
Key Executives
Chairman/Independent Director
Stephen Berenson
President/Chief Executive Officer/Director
Eric Shaff
Chief Financial Officer/Executive Vice President
David Arkowitz
Executive Vice President/Chief Technology Officer
John Aunins
Executive Vice President/Chief Technology Officer
David Ege
Executive Vice President/Chief Scientific Officer
Matthew Henn
Executive Vice President/Secretary
Thomas DesRosier
Executive Vice President
Lisa von Moltke
Executive Vice President
Teresa Young
Senior Vice President - Finance/Chief Accounting Officer
Marcus Chapman
Independent Director
Dennis Ausiello
Independent Director
Gregory Behar
Independent Director
Paul Biondi
Independent Director
Willard Dere
Independent Director
Kurt Graves
Independent Director
Richard Kender
Independent Director
Meryl Zausner
No Data
  • All
  • Financials
  • Insiders
More
About MCRB
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.

Webull offers kinds of Seres Therapeutics Inc stock information, including NASDAQ:MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.